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Poster Session I S211At 7 years, the cumulative proportion of those receiving 2nd trans-
plants is 40% (95% CI: 23%, 61%) It should be noted that median
follow-up time for those who have not yet received a second trans-
plant is only 14 months and 75% of these pts have been followed
for 32 months or less. Thus, in a more mature database with longer
follow-up the proportion of those receiving a second transplant may
increase.
Conclusion: We need guidelines for cryopreservation of HSC for
MM pts based on prospective evaluation to best utilize stem cell lab-
oratory resources.
Table 1. Demographic and Disease Characteristics
Cryopreserved HSC UsedAnalysis Results
Median (Range):
Independent variable
Starting TNC
MNC content
Starting CD341Ce
Starting CD31Cell
Hrs from Collection
TNC/mLM
8.
76
lls 5.
s 1.
23
#5
EDIAN (RANGE) U
0E10 (9.5E9 -1.2E11) 0
.3% (26.3 -92.1%) N
5E8 (1.1E8 -2.6E9) \
7E10 (3.6E9-4.2E10) N
(4 -55) N
4E8 vs .4E8 0Yes No
Yes5 17 No5 235 SignificanceAge (Mean, SEM) 54 (1.8) 57 (0.6) 0.25
Race 0.35Black 3 (18%) 75 (32%)
White 14 (82%) 155 (66%)
Other 0 (–) 5 (2%)Gender 0.005
Female 2 (12%) 107 (46%)
Male 15 (88%) 128 (54%)Stage* 0.49
I 0 22 (9%)
II 8 (47%) 51 (22%)
III 9 (53%) 161 (69%)* Durie Salmon Staging SystemGRAFT PROCESSING
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FACTORS AFFECTING CD34 + CELL PURITY, CD34 + CELL RECOVERY,
AND LOG T CELL DEPLETION OF PRODUCTS PROCESSED FOR CD34-EN-
RICHMENT ON THE ISOLEX— CELL SEPARATION DEVICE. A SINGLE CEN-
TER EXPERIENCE
Keever-Taylor, C.A.1, Zhang, L.2, Konings, S.1, Skonecki, J.A.1,
Zheng, H.1, Heidtke, S.A.1 1Medical College of Wisconsin, Milwaukee,
WI; 2Emmes Corporation, Rockville, MD
CD34-enrichment is commonly used as a method for the rigorous
removal of T cells from products used for hematopoietic progenitor
cell transplantation. Published reports have consistently shown
a high level of T cell depletion (TCD) and a high degree of purity
in the CD34-enriched products. Recovery of CD34+ cells from the
starting fraction has been more variable both within and between
centers. We performed univariate (UV) and multi-variable analysis
(MV) of 106 enrichment procedures of products obtained from 59
allogeneic donors to determine factors affecting CD34+ cell recov-
ery, log TCD, and product purity. Variables assessed included: the
number and concentration of total nucleated cells (TNC) loaded
onto the column, starting mononuclear cell (MNC) content, the
number of starting CD34+ and CD3+ cells, and time from the end
of collection to the start of selection. The analysis used a mixedCD341Cell Re
3.9% (18.3-96.1%)
V M
.0007 -
S -
0.0001 \
S -
S -
.0001 0effect model to adjust for multiple observations from the same do-
nors. Factors found to be associated with better CD34+ cell recov-
ery in the UV included fewer starting TNC, loading concentration
#4.0E8 TNC/mL, and fewer starting CD34+ cells. Using back-
ward selection, in the MV only starting CD34+ cells and TNC/
mL remained independently associated with recovery. Indeed, me-
dian CD34+ cell recovery was 63.5% at the lowest quartile of
starting CD34+ cell numbers (1.1E8 -3.6E8) and fell progressively
to 56.5% (3.7E8-5.4E8), 55.0% (5.5E8-7.3E8), and 42.9% (7.5E8-
2.6E9) for the 2nd, 3rd, and 4th quartiles, respectively. The addi-
tional effect of TNC/mL was seen regardless of time from collec-
tion to start of selection and there was no association of TNC/mL
and starting or ending product viability. CD34+ cell purity was
greatest at higher starting numbers of TNC and CD34+ cells
and at lower MNC content. Here a median CD34+ cell purity
of 93.4% was seen for the lowest quartile of starting CD34+ cells
versus 98.6% for the highest quartile. Starting CD34+ cells was
the only variable affecting Log TCD (poorer TCD with more
starting CD34+ cells). In conclusion, CD34+ cell recovery using
the Isolex device can be maximized by restricting the number of
CD34+ cells loaded onto the column and by ensuring that the
TNC loaded are # 4.0E8 TNC/mL. Even though fewer starting
CD34+ cells may result in somewhat poorer final product purity,
T cell content in the final product was not increased.144
A COMPARISON OF IN-SITU CB COLLECTION: VAGINAL VS. CESAREAN
SECTION
Miller, S.1, Kuenne, S.1, Zarlengo, G.2, Stark, C.2, Quinones, R.1,
Freed, B.1 1UC Denver – ClinImmune Labs, Aurora, CO; 2Exempla
St. Joseph Hospital, Denver, CO
With a national cesarean birth rate of .30%, these deliveries
represent a significant source of umbilical cord blood. We there-
fore compared cord blood units (CBU) obtained from planned
cesarean (n5 104) and vaginal (n5 581) births at the same hos-
pital over a seven month period in 2009. In both cases, the CBU
were collected in situ, prior to delivery or removal of the pla-
centa. The cesarean collections were performed with a sterile
connecting device placed within the sterile field connected to
the CB collection bag outside the field. The mean volume and
total nucleated cell count of cesarean CBU (120 ml; 1.4  109
TNC) were 33% greater than vaginal CBU (90 ml; 0.9  109
TNC; p\0.0001). In addition, cesarean CBU had a 0% contam-
ination rate, compared to 7% for vaginal CBU. CD34+ cell
counts were only performed on those CBU that contained
.0.9  109 TNC; the post-processing CD34 counts were not
significantly different between cesarean (4.9  106) and vaginal
births (5.1  106). Deferrals for donor ineligibility and maternal
risks were only 5% in cesarean collections, compared to 11% of
vaginal cord blood donors. There were no safety issues identified
for mothers or babies with the cesarean collections. As a result of
the higher cord blood volume, lower contamination rates, and
fewer deferrals, cesarean collections resulted in a 78% increase
in banking efficiency. This study suggests that cesarean birthsDependent Variable
covery CD341Cell purity Log TCD
97.6%
(69.9-99.4%)
4.3 (3.5-5.0)
V UV MV UV MV
\0.0001 0.005 NS -
0.042 0.017 NS -
0.0001 \0.0001 \0.0001 0.015 0.015
NS - NS -
NS - NS -
.018 0.0002 - NS -
S212 Poster Session Icould dramatically increase the number and volume of cord
blood units collected.145
HEALTH ECONOMIC OUTCOME ANALYSIS OF STEM CELL MOBILIZATION
WITH GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PLUS
PLERIXAFOR VERSUS G-CSF ALONE IN PREPARATION FOR AUTOLOGOUS
STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NON-HODG-
KIN’S LYMPHOMAS (NHL)
Pusic, I.1, Kymes, S.M.2, Lambert, D.L.2, Gregory, M.2, DiPersio, J.F.1
1Washington University School of Medicine, Siteman Cancer Center, St.
Louis, MO; 2Washington University School of Medicine, Ophthalmology
and Visual Sciences, St. Louis, MO
Background: Most commonly used mobilization methods for
ASCT include G-CSF, however no standard approach has been es-
tablished. Plerixafor (Mozobil), a competitive inhibitor of
CXCR4, when given with G-CSF mobilizes more CD34 cells/
apheresis resulting in a higher total CD34 cells/kg yield. We con-
sider the cost-benefit of G-CSF plus plerixafor (G + P) vs G-CSF
alone (G) for stem cell mobilization in NHL patients undergoing
ASCT.
Methods: We constructed a decision analytic model comparing
G + P to G in patients with NHL. The probabilities in the model
were taken from a recent randomized trial at Washington Univer-
sity (n5 41) comparing these two mobilization regimens. In the
trial, patients received G + P or G+placebo for initial mobilization.
In both arms, if minimal goal of 2  106 CD34 cells/kg was not
achieved after 4 aphereses, remobilization was conducted with
G + P. The model estimated costs for mobilization and remobiliza-
tion, but didn’t consider the transplant. The payor perspective was
taken with allowed charges, including medication, estimated using
Medicare allowable.
Results: In the G + P arm all patients (21/21) achieved the minimal
goal of CD34 cells after initial mobilization and proceeded to ASCT,
while in the G arm only 12/20 proceeded to ASCT. Of 8/20 remain-
ing G-patients, 2 were never remobilized, 6 were remobilized, but of
these only 4/6 achieved the minimal CD34 cell count required and
proceeded to ASCT. Adjusting for the lower enrollment in the G
arm, total allowed charges for mobilization of patients in the G + P
arm was $109,480 more than patients in the G arm. Had additional
mobilization been attempted for those patients in the G arm who
failed mobilization or remobilization (n5 4), the costs in the G
arm would have increased by $69,512, reducing the difference be-
tween groups to $39,968. We didn’t consider treatment or social
costs associated with the decision not to transplant following a failed
mobilization, as the events associated with these care processes were
not tracked in the trial. Conclusions: Taking a cost-benefit approach
we found that the G + P regimen in this trial cost $1,998 per patient
more than the G. This additional cost resulted in a 20% greater
probability of transplant in theG + P arm. Given the small difference
in cost, and large potential benefit, it is expected that future analyses
considering the social benefit of successful transplant will show that
the G + P regimen easily meets most accepted standards of cost-ef-
fectiveness.
G1 Placebo G1 PProbability of transplant 80.0% (16/20) 100% (21/21)
Probability of
remobilization
30.0% ( 6/20) N/ATotal cost per patient (SD) $ 12,458 (13,193) $ 17,932 (8,206)
Incremental cost per
patient
$ 5,474Estimated cost per
remobilization*$ 17,376Incremental cost after
adjustment for failed
mobilization$ 1,998*Remobilization protocol included plerixfor146
HEMATOPOIETIC STEM CELL APHERESIS PRODUCTS WITH HIGH MID-
COLLECTIONWBC COUNTS ARE AN ACCURATE INDICATOROF THE FINAL
PRODUCT WBC COUNT AND ARE ASSOCIATED WITH TRANSPLANT RE-
LATED ADVERSE EVENTS
Islas-Ohlmayer, M.1, Potter, G.W.2, Shaughnessy, P.2, LeMaistre, C.F.2,
Huerta, J.2, Folkert, J.2, Bachier, C.2 1University of Texas Health Science
Center at San Anonio, TX; 2Texas Transplant Institute, San Antonio, TX
We randomly reviewed 159 patients (pts) at our institution who
underwent hematopoietic stem cell (HSC) collection with either
a COBE spectra cell separator (CS) (n5 85) or Fresenius AS 104
cell separator (F) (n5 74). Products collected using the CS had
higher total WBC count when compared to the F (163 +/- 136 K/
uL vs. 55 +/- 29 K/uL, p\0.001) but a lower percentage of mono-
nuclear cells (MNC) (75% +/- 23% vs. 85% +/- 11%, p\0.001).
Unexpected transplant related adverse events were seen in 3 pts
who experienced tonic-clonic seizures and 1 pt with delayed engraft-
ment. These pts all received HSC apheresis products with WBC
counts over 590 K/uL, which was significantly higher than the me-
dian WBC counts on all apheresis products, and all were collected
using CS. No apheresis products were diluted prior to cryopreserva-
tion or infusion.
We subsequently reviewed 21 consecutive HSC apheresis prod-
ucts from 13 separate pts and analyzed WBC, MNC, and CD34
cell counts at 3 different time points, pre, mid and post-collec-
tion. Apheresis products with WBC counts greater than 400 K/
uL were diluted with normal saline (NS) prior to cryopreserva-
tion. Pts’ diagnoses were comprised only of hematological malig-
nancies, and included both auto (n5 19) and allogeneic (n5 2)
HSC collections. Products were collected using the CS (n5 10)
and the F (n5 11). Two pts had post collection WBC counts
over 400 K/uL and both were collected using the CS. Both prod-
ucts were diluted with NS prior to cryopreservation. One of the
two products was associated with delayed engraftment and 84%
donor chimerism at day 100. No other transplant related adverse
events were identified.
Analysis of the pre, mid, and post cell counts on theHSC apheresis
products revealed mid WBC values that accurately predicted post
apheresis product WBC counts (Table). The ease and rapidity of
mid apheresis WBC count analysis may allow the apheresis proce-
dure to be modified if WBC counts greater than 400 K/ul are pre-
dicted. We plan to prospectively assess mid WBC counts on all
apheresis procedures that use CS. Products with mid
WBC. 400 K/uL will get additional plasma collected so the final
product can be diluted with autologous plasma. Accurate and timely
identification of high risk apheresis products can obviate the unnec-
essary dilution of all products and therefore help decrease the cost
associated with cryopreservation of apheresed HSC products.
WBC, MNC and CD 34 Cell Counts Mid and Post Apheresis
WBC (k/uL) MNC (%) CD34x106/kgCOBE MID POST MID POST MID POSTMEAN 1/- SD 273 1/- 230 281 1/- 186 76 1/- 22 86 1/- 16 3 1/- 4 6 1/- 8RANGE 819 596 75 53 9 23FRESENIUS MID POST MID POST MID POSTMEAN 1/- SD 71 1/- 22 75 1/- 20 88 1/- 5 90 1/- 5 1 1/- 0.8 2 1/- 1RANGE 69 67 20 16 2 4Mid - cell counts mid way through a 10-12 L collection, Post -cell counts
at the end of a 20-24 L collection147
RELATIVE EFFICIENCY OF CORD BLOOD RBC DEPLETION BY SEPAX ELU-
TRIATION AND MANUAL REDUCTION
Miller, C.N., Miller, S.N., Flannery, S., Stockinger, S., Gutman, J.,
Quinones, R., Freed, B.M. University of Colorado Denver ClinImmune
Labs, Aurora, CO
Infusion of cord blood units with high RBC volume has been re-
ported to increase the health risk for recipients. Therefore the
